NICE approves docetaxel for early breast cancerBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7571.720-d (Published 05 October 2006) Cite this as: BMJ 2006;333:720
- Susan Mayor
New guidance for the NHS published this week recommends docetaxel (Taxotere) to treat women with early, node positive breast cancer after surgery. Use of another taxane, paclitaxel (Taxol), is not recommended in the final guidance.
The guidance, issued by the National Institute for Health and Clinical Excellence (NICE), the body that advises on the use of treatments by the NHS in England and Wales, overturned draft guidance that had recommended against the use of docetaxel.
At the time the appraisal committee found that there was “too much uncertainty about the evidence to make a clear judgment on its clinical and cost effectiveness compared with current practice in England and Wales” (bmj.com, 6 May 2006, News Extra).
NICE asked for more information on the clinical and cost effectiveness of docetaxel in combination with doxorubicin and cyclophosphamide when compared with currently …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial